Actemra Inhibits Joint Damage And Improves Physical Function Of Patients With Rheumatoid Arthritis
May 10th, 2008 | by admin |Roche announced that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients’ physical function after one year of therapy, leading to a better quality of life.
Original post by Allergy News From Medical News Today
Stumble it!